ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

- November 8th, 2018

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today reported financial results for the quarter ended 30 September 2018 and provided an update on its clinical activities. As quoted in the press release: Dr Carl Firth, Chief … Continued

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today reported financial results for the quarter ended 30 September 2018 and provided an update on its clinical activities.

As quoted in the press release:

Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said: “We made further progress across our clinical development programs in the third quarter with the completion of enrolment in the phase 2 part of our gastric cancer study for varlitinib, our pan-HER inhibitor, and the dosing of our first subject in a phase 1 study for ASLAN004, our IL-4/IL-13 receptor antibody. In addition, we were pleased that the US FDA granted ASLAN003 Orphan Drug Designation for the potential treatment of AML and we continued our outreach to the scientific community with a number of poster presentations at key medical meetings. We also recently took the step of strengthening our board with the addition of Robert E. Hoffman as a director of the company. Looking ahead, we have a number of potentially value-creating milestones in the near term, including readouts from our AML, biliary tract and gastric cancer programs.”

Click here to read the full press release.

Is it a good time to buy gold stocks?


Learn to profit from gold's low price this year!

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *